Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.
Pediatr Dermatol
; 41(5): 819-821, 2024.
Article
em En
| MEDLINE
| ID: mdl-39049669
ABSTRACT
INTRODUCTION:
At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).METHODS:
Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.RESULTS:
58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.CONCLUSIONS:
Aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prurido
/
Epidermólise Bolhosa
/
Dermatite Atópica
/
Aprepitanto
Limite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Pediatr Dermatol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos